gastric cancer

News

BMS ducks out of $1.56bn TIGIT alliance with Agenus

Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.

Oncology

ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

News

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment

News

FDA blocks Astellas’ Claudin cancer drug over manufacturing

Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug can

News

Keytruda gets front-line gastric cancer okay in EU

The European Commission has given approval to MSD's Keytruda as a first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

BMS ducks out of $1.56bn TIGIT alliance with Agenus

ASCO 2024 - Michael Petroutsas

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

FDA blocks Astellas’ Claudin cancer drug over manufacturing

Keytruda gets front-line gastric cancer okay in EU

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

gastric cancer

Editor's Picks